Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906037 | 0.84 | GRM4 (0.48) | KMT2ARAB9AMEN1ALDH1A1MAPT | |
| SCHEMBL3571026 | 0.83 | RAB9A (0.58) | KMT2ARAB9AMEN1NPC1ALDH1A1 | |
| SCHEMBL3571028 | 0.83 | RAB9A (0.58) | KMT2ARAB9AMEN1NPC1ALDH1A1 | |
| SCHEMBL27030120 | 0.81 | ALDH1A1 (0.48) | KMT2ARAB9AMEN1NPC1ALDH1A1 | |
| SCHEMBL30355109 | 0.81 | ALDH1A1 (0.48) | KMT2ARAB9AMEN1NPC1ALDH1A1 | |
| SCHEMBL3973117 | 0.78 | RAB9A (0.53) | KMT2ARAB9AMEN1NPC1TDP1 | |
| SCHEMBL3973119 | 0.78 | RAB9A (0.53) | KMT2ARAB9AMEN1NPC1TDP1 | |
| SCHEMBL2321687 | 0.78 | RAB9A (0.53) | KMT2ARAB9AMEN1NPC1TDP1 | |
| SCHEMBL23892228 | 0.78 | KMT2A (0.42) | KMT2ARAB9AMEN1NPC1TDP1 | |
| SCHEMBL9293883 | 0.77 | HIF1A (0.61) | KMT2ARAB9AMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | KMT2A 3308/4885RAB9A 616/4885MEN1 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.